Home / Recalls / Edge Pharma, LLC / D-0421-2022

D-0421-2022 Class II Terminated

Recalled by Edge Pharma, LLC — Colchester, VT

Recall Details

Product Type
Drugs
Report Date
February 2, 2022
Initiation Date
December 6, 2021
Termination Date
June 7, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2562 syringes

Product Description

Phenylephrine HCl/Tropicamide/Cyclopentolate HCl/Ketorolac Sterile Ophthalmic Solution, 2.5%/0.25%/0.25%/0.125%, 0.5 mL syringe, Single Use Syringe, For Topical Ophthalmic Use, NDC 05446-0993-01

Reason for Recall

Lack of Assurance of Sterility

Distribution Pattern

nationwide

Code Information

09-2021-15@2 12/28/2021 & 11-2021-02@3 02/14/2022

Other recalls by Edge Pharma, LLC

  • D-0412-2022 Class II — MVASI, (bevacizumab-awwb), Sterile Ophthalmic Solution for Injection, 3.25mg/0.1 (December 6, 2021)
  • D-0430-2022 Class II — Cantharidin PLUS, Cantharidin/Salicylic Acid Gel-Forming Suspension, 10 mL per v (December 6, 2021)
  • D-0403-2022 Class II — Gemcitabine, Sterile Intravesical Solution, Preservative Free, 1g/50mL (20 mg/mL (December 6, 2021)
  • D-0448-2022 Class II — Vancomycin HCl Oral Solution (PF) 125mg / 2.5mL (50 mg/mL), 2.5 mL per syringe, (December 6, 2021)
  • D-0419-2022 Class II — Phenylephrine HCl/Lidocaine, Sterile Ophthalmic Solution for Injection, Preserva (December 6, 2021)
  • D-0405-2022 Class II — Methacholine Challenge 5-Syringe Test Kit, Sterile Inhalation Solution, Preserva (December 6, 2021)
  • D-0432-2022 Class II — CSF-HC Otic Insufflation Capsule, Sulfacetamide Sodium/Ciprofloxacin/Hydrocortis (December 6, 2021)
  • D-0429-2022 Class II — Cantharidin Gel-Forming Suspension, 0.7%, 10 mL per vial, Multiple Dose Vial for (December 6, 2021)
  • D-0442-2022 Class II — Profound-PE Dental Gel, Lidocaine HCl/Prilocaine HCl/Tetracaine HCl/Phenylephrin (December 6, 2021)
  • D-0423-2022 Class II — Betadine (povidone-iodine), Sterile Ophthalmic Solution, Preservative Free, 5% 0 (December 6, 2021)